Published in Transl Oncogenomics on November 23, 2015
CREATE: Cross-tumoral Phase 2 With Crizotinib (CREATE) | NCT01524926
Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer | NCT01548144
A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer | NCT01663272
Dasatinib and Crizotinib in Advanced Cancer | NCT01744652
Sorafenib or Crizotinib and Vemurafenib in Advanced Cancer | NCT01531361
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer | NCT02019693
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. World J Gastroenterol (2016) 0.82
The Multiple Roles of Exosomes in Metastasis. Cancer Genomics Proteomics (2016) 0.81
Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy. Drug Des Devel Ther (2016) 0.80
Mechanisms and Targets Involved in Dissemination of Ovarian Cancer. Cancer Genomics Proteomics (2016) 0.80
Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician. Eur J Nucl Med Mol Imaging (2017) 0.78
PKG II reverses HGF-triggered cellular activities by phosphorylating serine 985 of c-Met in gastric cancer cells. Oncotarget (2016) 0.77
The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis. Sci Rep (2016) 0.75
Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer. World J Clin Oncol (2016) 0.75
Expression and clinicopathological implication of DcR3 in lung cancer tissues: a tissue microarray study with 365 cases. Onco Targets Ther (2016) 0.75
MicroRNA-613 suppresses proliferation, migration and invasion of osteosarcoma by targeting c-MET. Am J Cancer Res (2016) 0.75
The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models. Am J Cancer Res (2017) 0.75
Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice. Ther Adv Med Oncol (2017) 0.75
Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma. Cancers (Basel) (2017) 0.75
A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors. Invest New Drugs (2016) 0.75
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med (2011) 16.94
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science (2002) 14.50
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell (2009) 13.09
The STATs of cancer--new molecular targets come of age. Nat Rev Cancer (2004) 13.07
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene (2007) 11.85
NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer (2002) 11.39
First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med (2014) 10.91
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet (1994) 10.14
MAP kinase signalling pathways in cancer. Oncogene (2007) 8.52
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell (2003) 6.59
Targeting MET in cancer: rationale and progress. Nat Rev Cancer (2012) 6.43
Scatter factor/hepatocyte growth factor is essential for liver development. Nature (1995) 5.91
Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature (1984) 5.85
MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol (2010) 5.44
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2013) 5.21
Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol (1992) 5.04
Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov (2008) 4.76
Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature (1995) 4.68
Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol (2007) 4.12
A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell (1994) 4.10
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol (2012) 3.92
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol (2012) 3.88
Stromal biology and therapy in pancreatic cancer. Gut (2010) 3.80
Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer (2014) 3.70
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol (2009) 3.57
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol (2009) 3.53
Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol (2013) 3.37
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol (2011) 3.27
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett (2004) 3.17
Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol (2005) 2.96
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov (2013) 2.87
Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res (1995) 2.84
Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature (1998) 2.83
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2014) 2.67
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol (1997) 2.54
Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene (2000) 2.52
Non-small cell lung cancer. J Natl Compr Canc Netw (2012) 2.40
PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol (2012) 2.39
The mTOR signalling pathway in human cancer. Int J Mol Sci (2012) 2.38
Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol (2011) 2.32
c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology (2011) 2.27
Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell (2001) 2.26
C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer (2005) 2.25
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol (2011) 2.19
ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther (2010) 2.18
HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res (2010) 2.11
The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol (2000) 2.07
Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem (1995) 2.06
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res (2009) 2.01
Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor. EMBO J (2004) 1.94
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2014) 1.93
c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol (2011) 1.81
The Met proto-oncogene mesenchymal to epithelial cell conversion. Science (1994) 1.77
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res (2010) 1.71
MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array. Clin Cancer Res (2014) 1.71
MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol (2012) 1.71
Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med (2012) 1.69
Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res (2011) 1.67
Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol (2001) 1.64
miR-340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c-Met. Cancer (2011) 1.60
A novel role for Gab1 and SHP2 in epidermal growth factor-induced Ras activation. J Biol Chem (2004) 1.44
The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. Oncogene (1995) 1.38
Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res (2013) 1.35
A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol (2014) 1.33
Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci (2008) 1.31
MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J Thorac Oncol (2011) 1.29
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res (2015) 1.29
MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res (2010) 1.28
Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One (2013) 1.28
AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res (2007) 1.27
A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res (2011) 1.27
High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histol Histopathol (2012) 1.26
Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res (2002) 1.26
Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. Br J Cancer (2012) 1.24
A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol (2011) 1.23
Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene (2005) 1.19
Activation of NF-kappaB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis. Mol Cell Biol (2002) 1.18
Head neck squamous cell carcinoma c-Met⁺ cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis. Int J Cancer (2011) 1.17
The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. Cell Death Dis (2013) 1.17
Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. Oncogenesis (2013) 1.13
Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res (2012) 1.13
MET mutations in cancers of unknown primary origin (CUPs). Hum Mutat (2010) 1.13
MicroRNA-449a is downregulated in non-small cell lung cancer and inhibits migration and invasion by targeting c-Met. PLoS One (2013) 1.12
Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma. Int J Oncol (2013) 1.10
Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. Cancer Chemother Pharmacol (2012) 1.09
MEKK2 regulates the coordinate activation of ERK5 and JNK in response to FGF-2 in fibroblasts. J Cell Physiol (2004) 1.09
The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance. Pharmacol Ther (2013) 1.07
TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. Mol Cancer Ther (2010) 1.07
A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. J Biol Chem (2008) 1.06
Met as a therapeutic target in HCC: facts and hopes. J Hepatol (2013) 1.03
Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102. J Cell Mol Med (2010) 1.03
A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int (2010) 1.03
Expression and prognostic significance of CD151, c-Met, and integrin alpha3/alpha6 in pancreatic ductal adenocarcinoma. Dig Dis Sci (2010) 1.03